Pfizer Beats on Q3, Raises 2026 Revenue Guidance to $62-64B and EPS to $2.95-$3.05
PFE sits 30% above its 52-week low of $23.62.
Summary
Pfizer reported Q3 2026 revenue of $16.6 billion, flat year-over-year but up 7% excluding COVID products, and raised full-year revenue guidance to $62-64 billion and adjusted EPS to $2.95-$3.05. Adjusted EPS of $0.87 matched last year despite $4.3 billion of nine-month impairments.
Updates
· Benzinga — Pfizer's Q3 non-COVID portfolio grew 7% operationally, with Eliquis sales up 25% to $2.52 billion and Padcev up 55% to $720 million; shares fell 1.01% to $30.36.
- Q3 Results vs Consensus — Q3 revenue of $16.58 billion beat consensus of $15.87 billion, and adjusted earnings of 87 cents per share beat the consensus of 72 cents.
- Raised Guidance — 2026 sales guidance raised to $62 billion to $64 billion from $60.5 billion to $62.5 billion, versus consensus of $62.17 billion; adjusted EPS guidance raised to $2.95 to $3.05 per share from $2.80 to $3.00 per share, versus consensus of $2.96.
- Growth Drivers — Launched and acquired products contributed $3.8 billion in revenues, and Vyndaqel family sales rose 12% to $1.77 billion; Nurtec and Lorbrena were cited among brands whose higher revenues largely offset lower COVID-19 and Prevnar revenues.
- COVID and Prevnar Declines — Paxlovid sales fell 63% to $449 million, Comirnaty revenues were $808 million, down 29%, and Prevnar family sales fell 10% to $1.56 billion.
All 10 details
- Q3 revenue $16.58 billion beat consensus of $15.87 billion
- Adjusted earnings 87 cents per share, beating the consensus of 72 cents
- Launched and acquired products contributed $3.8 billion in revenues
- Vyndaqel family sales rose 12% to $1.77 billion
- Paxlovid sales fell 63% to $449 million
- Comirnaty revenues were $808 million, down 29%
- Prevnar family sales fell 10% to $1.56 billion
- 2026 sales guidance raised to $62 billion to $64 billion, from $60.5 billion to $62.5 billion, versus consensus of $62.17 billion
- 2026 adjusted EPS guidance raised to $2.95 to $3.05 per share, from $2.80 to $3.00 per share, versus consensus of $2.96
- Nurtec and Lorbrena cited among brands whose higher revenues largely offset lower revenues from COVID-19 products and the Prevnar family
Key Events · Earnings and Guidance · PFE
-
Q3 Revenue Flat, Non-COVID Up 7%
Third-quarter 2026 revenues were $16.6 billion, down $71 million year-over-year, but excluding Comirnaty and Paxlovid revenue grew 7% operationally and launched and acquired products grew 32%.
-
Guidance Raised on Strong Year-to-Date
Full-year 2026 revenue guidance rose $1.5 billion at the midpoint to $62.0-$64.0 billion from $60.5-$62.5 billion, and adjusted diluted EPS guidance rose to $2.95-$3.05 from $2.80-$3.00.
-
Adjusted EPS Holds at $0.87
Reported diluted EPS fell to $0.56 from $0.62, while adjusted diluted EPS was flat at $0.87; nine-month reported net income fell 40% to $5.68 billion on $4.325 billion of asset impairments.
-
New CFO Effective November 1
Cecile Guegan was appointed Chief Financial Officer and Executive Vice President effective November 1, 2026, and spoke on the quarter.
Analysis · PFE · Life Sciences
The headline top line looks flat, but the mix underneath is far stronger: excluding COVID products, revenue grew 7% operationally, and the launched and acquired portfolio grew 32%. That gave management room to lift full-year revenue guidance by $1.5 billion at the midpoint and raise the adjusted EPS floor by $0.15. Nine-month impairments of $4.3 billion, mostly the $3.8 billion sigvotatug vedotin write-off, explain why reported EPS fell to $0.56 from $0.62 while adjusted EPS held at $0.87. A new CFO, Cecile Guegan, took over November 1, and the company confirmed no buybacks in 2026 with $3.3 billion still authorized — capital is going to the dividend and de-levering instead.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PFE was trading at $30.62 on NYSE in the Life Sciences sector, with a market capitalization of approximately $174.8B. The 52-week trading range was $23.62 to $31.04. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.